Trade Report: Today, Boston Common Asset Management LLC Cuts Stake in Qiagen NV (QGEN)

Today, Boston Common Asset Management LLC Cuts Stake in Qiagen NV (QGEN)

Boston Common Asset Management LLC cut its position in Qiagen NV (NASDAQ:QGEN) by 0.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 88,242 shares of the company’s stock after selling 825 shares during the period. Boston Common Asset Management LLC’s holdings in Qiagen NV were worth $2,421,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently made changes to their positions in the company. State Street Corp increased its position in Qiagen NV by 3.0% in the first quarter. State Street Corp now owns 2,094,136 shares of the company’s stock valued at $46,785,000 after buying an additional 61,463 shares during the period. Private Bank & Trust Co. increased its position in Qiagen NV by 17.8% in the second quarter. Private Bank & Trust Co. now owns 10,609 shares of the company’s stock valued at $231,000 after buying an additional 1,606 shares during the period. Nisa Investment Advisors LLC increased its position in Qiagen NV by 4.7% in the second quarter. Nisa Investment Advisors LLC now owns 13,400 shares of the company’s stock valued at $292,000 after buying an additional 600 shares during the period. Acadian Asset Management LLC increased its position in Qiagen NV by 29.9% in the second quarter. Acadian Asset Management LLC now owns 356,297 shares of the company’s stock valued at $7,763,000 after buying an additional 82,005 shares during the period. Finally, Bank of Montreal Can bought a new position in Qiagen NV during the second quarter valued at approximately $12,050,000. Institutional investors own 56.50% of the company’s stock.

Shares of Qiagen NV (NASDAQ:QGEN) traded down 0.22% during midday trading on Friday, hitting $27.52. The company had a trading volume of 78,807 shares. Qiagen NV has a one year low of $19.94 and a one year high of $28.50. The stock has a market capitalization of $6.45 billion, a price-to-earnings ratio of 55.04 and a beta of 1.07. The stock’s 50-day moving average price is $26.53 and its 200-day moving average price is $24.70.

Qiagen NV (NASDAQ:QGEN) last issued its quarterly earnings results on Wednesday, November 2nd. The company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.28 by $0.01. The business earned $338.70 million during the quarter, compared to analysts’ expectations of $335.46 million. Qiagen NV had a return on equity of 9.34% and a net margin of 8.96%. The firm’s revenue for the quarter was up 7.7% compared to the same quarter last year. During the same period in the previous year, the company posted $0.27 earnings per share. Analysts predict that Qiagen NV will post $1.03 EPS for the current year.

Several equities analysts recently commented on QGEN shares. Zacks Investment Research upgraded Qiagen NV from a “hold” rating to a “buy” rating and set a $29.00 target price for the company in a research report on Wednesday, September 14th. DZ Bank AG reaffirmed a “buy” rating on shares of Qiagen NV in a report on Monday, September 12th. Commerzbank AG reaffirmed a “buy” rating on shares of Qiagen NV in a report on Wednesday, August 31st. Jefferies Group reaffirmed a “hold” rating on shares of Qiagen NV in a report on Thursday, August 4th. Finally, Barclays PLC reaffirmed a “buy” rating and set a $28.00 price target on shares of Qiagen NV in a report on Thursday, November 3rd. Seven analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Qiagen NV presently has an average rating of “Buy” and a consensus target price of $26.60.

Qiagen NV Company Profile

QIAGEN N.V. (QIAGEN) is a holding company. The Company and its subsidiaries are engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Sample to Insight solutions are composed of sample and assay technologies, bioinformatics and automation systems.

Related posts

Leave a Comment